Live Breaking News & Updates on Taiho Pharmaceutical About|Page 1

Stay updated with breaking news from Taiho pharmaceutical about. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FDA Approves Taiho's LYTGOBI® (futibatinib) Tablets for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

LYTGOBI (pronounced light-GOH-bee ) delivered an objective response rate of 42% and median duration of response of 9.7 months in the primary anal. ....

New Jersey , United States , Teruhiro Utsugi , Lipika Goyal , Judy Kay Moore , Tim Whitten , Taiho Oncology Inc , Taiho Pharmaceutical Co Ltd , Hospital Cancer Center , Drug Administration , Otsuka Holdings Co Ltd , Prnewswire Taiho Oncology Inc , Taiho Oncology , Massachusetts General Hospital Cancer Center , Taiho Pharmaceutical , Senior Managing Director , Taiho Pharmaceutical About , Pigment Epithelial Detachment , Corneal Keratitis , Soft Tissue Mineralization , Prescribing Information , Oncology Media Contact ,